Andreas Tiede/ResearchGate
Dec 8, 2025, 11:08
Andreas Tiede: This Will Change Hematology Forever
Andreas Tiede, Professor, Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, shared on LinkedIn:
”This will change Hematology forever: the milder Aza/Ven combination is more effective and less harmful than the traditional 3+7 chemo regimen in fit AML patients.
Groundbreaking data at ASH2025”
The American Society of Hematology Congress 2025 (ASH25) is officially underway in Orlando, Florida, from December 6 to 9.
It aims to bring together hematology professionals from across the globe.
Throughout the meeting, experts will present new research, clinical breakthroughs, and innovations that are defining the future of hematologic care.
More from ASH25 featured in Hemostasis Today.
-
Jul 26, 2026, 16:26Novi Yanti Sari: When MPNs Affect the Heart
-
Jul 26, 2026, 16:21Beyond Drugs: Can Museums Become a Medical Prescription?
-
Jul 26, 2026, 14:45Sarah Giorgia Grazia Giannone: An Exciting Chapter in Gene Therapy Research
-
Jul 26, 2026, 14:21Javed Anees: Cerebral Collateral Circulation in Acute Ischemic Stroke
-
Jul 26, 2026, 14:11André Picard։ Canadian Blood Supplies Drop Sharply, Urgent Donor Appeal Issued
-
Jul 26, 2026, 13:54Lorenzo Scalia: New Review Highlights Anticoagulant Strategies for Elderly Patients With Atrial Fibrillation
-
Jul 26, 2026, 13:32Ahmed Kotb: A Practical Guide to Von Willebrand Disease
-
Jul 26, 2026, 12:42Emmanuel J Favaloro: Celebrating Excellence in Scientific Peer Review
-
Jul 26, 2026, 12:20Advancing Sickle Cell Care Through Advocacy – American Society of Hematology